Copyright Reports & Markets. All rights reserved.

Global Nuclear Radiopharmaceutical Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Nuclear Radiopharmaceutical Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Diagnostic Radiopharmaceuticals
    • 1.3.3 Therapeutic Radiopharmaceuticals
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Nuclear Radiopharmaceutical Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Oncology
    • 1.4.3 Thyroid
    • 1.4.4 Cardiology
    • 1.4.5 Others
  • 1.5 Global Nuclear Radiopharmaceutical Market Size & Forecast
    • 1.5.1 Global Nuclear Radiopharmaceutical Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Nuclear Radiopharmaceutical Sales Quantity (2021-2032)
    • 1.5.3 Global Nuclear Radiopharmaceutical Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Cardinal Health
    • 2.1.1 Cardinal Health Details
    • 2.1.2 Cardinal Health Major Business
    • 2.1.3 Cardinal Health Nuclear Radiopharmaceutical Product and Services
    • 2.1.4 Cardinal Health Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Cardinal Health Recent Developments/Updates
  • 2.2 GE Healthcare
    • 2.2.1 GE Healthcare Details
    • 2.2.2 GE Healthcare Major Business
    • 2.2.3 GE Healthcare Nuclear Radiopharmaceutical Product and Services
    • 2.2.4 GE Healthcare Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 GE Healthcare Recent Developments/Updates
  • 2.3 Jubilant Pharma
    • 2.3.1 Jubilant Pharma Details
    • 2.3.2 Jubilant Pharma Major Business
    • 2.3.3 Jubilant Pharma Nuclear Radiopharmaceutical Product and Services
    • 2.3.4 Jubilant Pharma Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Jubilant Pharma Recent Developments/Updates
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Nuclear Radiopharmaceutical Product and Services
    • 2.4.4 Novartis Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments/Updates
  • 2.5 Curium Pharma
    • 2.5.1 Curium Pharma Details
    • 2.5.2 Curium Pharma Major Business
    • 2.5.3 Curium Pharma Nuclear Radiopharmaceutical Product and Services
    • 2.5.4 Curium Pharma Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Curium Pharma Recent Developments/Updates
  • 2.6 SIEMENS
    • 2.6.1 SIEMENS Details
    • 2.6.2 SIEMENS Major Business
    • 2.6.3 SIEMENS Nuclear Radiopharmaceutical Product and Services
    • 2.6.4 SIEMENS Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 SIEMENS Recent Developments/Updates
  • 2.7 Lantheus
    • 2.7.1 Lantheus Details
    • 2.7.2 Lantheus Major Business
    • 2.7.3 Lantheus Nuclear Radiopharmaceutical Product and Services
    • 2.7.4 Lantheus Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Lantheus Recent Developments/Updates
  • 2.8 Bracco Imaging
    • 2.8.1 Bracco Imaging Details
    • 2.8.2 Bracco Imaging Major Business
    • 2.8.3 Bracco Imaging Nuclear Radiopharmaceutical Product and Services
    • 2.8.4 Bracco Imaging Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Bracco Imaging Recent Developments/Updates
  • 2.9 Bayer
    • 2.9.1 Bayer Details
    • 2.9.2 Bayer Major Business
    • 2.9.3 Bayer Nuclear Radiopharmaceutical Product and Services
    • 2.9.4 Bayer Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Bayer Recent Developments/Updates
  • 2.10 Eli Lilly
    • 2.10.1 Eli Lilly Details
    • 2.10.2 Eli Lilly Major Business
    • 2.10.3 Eli Lilly Nuclear Radiopharmaceutical Product and Services
    • 2.10.4 Eli Lilly Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Eli Lilly Recent Developments/Updates
  • 2.11 Aurobindo Pharma
    • 2.11.1 Aurobindo Pharma Details
    • 2.11.2 Aurobindo Pharma Major Business
    • 2.11.3 Aurobindo Pharma Nuclear Radiopharmaceutical Product and Services
    • 2.11.4 Aurobindo Pharma Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Aurobindo Pharma Recent Developments/Updates
  • 2.12 Mundipharma
    • 2.12.1 Mundipharma Details
    • 2.12.2 Mundipharma Major Business
    • 2.12.3 Mundipharma Nuclear Radiopharmaceutical Product and Services
    • 2.12.4 Mundipharma Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Mundipharma Recent Developments/Updates
  • 2.13 China Isotope & Radiation
    • 2.13.1 China Isotope & Radiation Details
    • 2.13.2 China Isotope & Radiation Major Business
    • 2.13.3 China Isotope & Radiation Nuclear Radiopharmaceutical Product and Services
    • 2.13.4 China Isotope & Radiation Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 China Isotope & Radiation Recent Developments/Updates
  • 2.14 Dongcheng
    • 2.14.1 Dongcheng Details
    • 2.14.2 Dongcheng Major Business
    • 2.14.3 Dongcheng Nuclear Radiopharmaceutical Product and Services
    • 2.14.4 Dongcheng Nuclear Radiopharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Dongcheng Recent Developments/Updates

3 Competitive Environment: Nuclear Radiopharmaceutical by Manufacturer

  • 3.1 Global Nuclear Radiopharmaceutical Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Nuclear Radiopharmaceutical Revenue by Manufacturer (2021-2026)
  • 3.3 Global Nuclear Radiopharmaceutical Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Nuclear Radiopharmaceutical by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Nuclear Radiopharmaceutical Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Nuclear Radiopharmaceutical Manufacturer Market Share in 2025
  • 3.5 Nuclear Radiopharmaceutical Market: Overall Company Footprint Analysis
    • 3.5.1 Nuclear Radiopharmaceutical Market: Region Footprint
    • 3.5.2 Nuclear Radiopharmaceutical Market: Company Product Type Footprint
    • 3.5.3 Nuclear Radiopharmaceutical Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Nuclear Radiopharmaceutical Market Size by Region
    • 4.1.1 Global Nuclear Radiopharmaceutical Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Nuclear Radiopharmaceutical Consumption Value by Region (2021-2032)
    • 4.1.3 Global Nuclear Radiopharmaceutical Average Price by Region (2021-2032)
  • 4.2 North America Nuclear Radiopharmaceutical Consumption Value (2021-2032)
  • 4.3 Europe Nuclear Radiopharmaceutical Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Nuclear Radiopharmaceutical Consumption Value (2021-2032)
  • 4.5 South America Nuclear Radiopharmaceutical Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Nuclear Radiopharmaceutical Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 5.2 Global Nuclear Radiopharmaceutical Consumption Value by Type (2021-2032)
  • 5.3 Global Nuclear Radiopharmaceutical Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 6.2 Global Nuclear Radiopharmaceutical Consumption Value by Application (2021-2032)
  • 6.3 Global Nuclear Radiopharmaceutical Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 7.2 North America Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 7.3 North America Nuclear Radiopharmaceutical Market Size by Country
    • 7.3.1 North America Nuclear Radiopharmaceutical Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Nuclear Radiopharmaceutical Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 8.2 Europe Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 8.3 Europe Nuclear Radiopharmaceutical Market Size by Country
    • 8.3.1 Europe Nuclear Radiopharmaceutical Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Nuclear Radiopharmaceutical Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Nuclear Radiopharmaceutical Market Size by Region
    • 9.3.1 Asia-Pacific Nuclear Radiopharmaceutical Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Nuclear Radiopharmaceutical Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 10.2 South America Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 10.3 South America Nuclear Radiopharmaceutical Market Size by Country
    • 10.3.1 South America Nuclear Radiopharmaceutical Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Nuclear Radiopharmaceutical Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Nuclear Radiopharmaceutical Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Nuclear Radiopharmaceutical Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Nuclear Radiopharmaceutical Market Size by Country
    • 11.3.1 Middle East & Africa Nuclear Radiopharmaceutical Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Nuclear Radiopharmaceutical Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Nuclear Radiopharmaceutical Market Drivers
  • 12.2 Nuclear Radiopharmaceutical Market Restraints
  • 12.3 Nuclear Radiopharmaceutical Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Nuclear Radiopharmaceutical and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Nuclear Radiopharmaceutical
  • 13.3 Nuclear Radiopharmaceutical Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Nuclear Radiopharmaceutical Typical Distributors
  • 14.3 Nuclear Radiopharmaceutical Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Nuclear Radiopharmaceutical market size was valued at US$ 7322 million in 2025 and is forecast to a readjusted size of US$ 11780 million by 2032 with a CAGR of 7.1% during review period.
    Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
    Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
    The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
    Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
    There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
    Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
    Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.
    This report is a detailed and comprehensive analysis for global Nuclear Radiopharmaceutical market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Nuclear Radiopharmaceutical market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nuclear Radiopharmaceutical market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nuclear Radiopharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nuclear Radiopharmaceutical market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Nuclear Radiopharmaceutical
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Nuclear Radiopharmaceutical market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Nuclear Radiopharmaceutical market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Diagnostic Radiopharmaceuticals
    Therapeutic Radiopharmaceuticals
    Market segment by Application
    Oncology
    Thyroid
    Cardiology
    Others
    Major players covered
    Cardinal Health
    GE Healthcare
    Jubilant Pharma
    Novartis
    Curium Pharma
    SIEMENS
    Lantheus
    Bracco Imaging
    Bayer
    Eli Lilly
    Aurobindo Pharma
    Mundipharma
    China Isotope & Radiation
    Dongcheng
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Nuclear Radiopharmaceutical product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Nuclear Radiopharmaceutical, with price, sales quantity, revenue, and global market share of Nuclear Radiopharmaceutical from 2021 to 2026.
    Chapter 3, the Nuclear Radiopharmaceutical competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Nuclear Radiopharmaceutical breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Nuclear Radiopharmaceutical market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Nuclear Radiopharmaceutical.
    Chapter 14 and 15, to describe Nuclear Radiopharmaceutical sales channel, distributors, customers, research findings and conclusion.

    Buy now